Commitments and Contingencies (Details Narrative) - USD ($)			9 Months Ended
	Feb. 05, 2024	Nov. 03, 2020	Sep. 30, 2024
Payments For Future Research And Collobration			$ 1,232,263
Total Grants Repayable			454,544
Principal balance payable			65,467
Aggerate Amount Payable, Description		under this agreement will be completed by the end of the third quarter of 2024 at a total additional cost to the Company of up to $0.7 million
Loan agreement, Description	9-month loan agreement with First Insurance Funding for a maximum of $294,603 with fixed interest rate of 8.42%, maturing in November 2024
Total Long-Term Debt			4,802,971
Amount payable for services rendered			138,971
Amount may be payable by Company in future periods for services rendered			0
Accrued compensation expense			536,535
Recognized total compensation expense			447,008
RSU 2023 [Member]
Unrecognized compensation expense			270,104
RSU 2024 [Member]
Unrecognized compensation expense			0
RSU 2025 [Member]
Unrecognized compensation expense			115,517
RSU 2026 [Member]
Unrecognized compensation expense			154,587
Two Thousand Twenty Two [Member] | Univercity Of Texas MD [Member]
Collaborative Obligations Amount Due			138,971
Additional Cost Of Company			327,092
Cost			327,092
August Two Thousand Twenty Three [Member] | Guy's and St Thomas' NHS Foundation Trust [Member]
Collaborative Obligations Amount Due			0
Additional Cost Of Company			217,464
Cost			217,464
July Thirty One Thousand Twenty Three [Member] | Xenetic Biosciences Inc and CLS Therapeutics [Member]
Collaborative Obligations Amount Due			26,142
Additional Cost Of Company			81,447
Cost			107,589
January TwoThousand Twenty Four [Member] | University Medical Centre Amsterdam[Member]
Collaborative Obligations Amount Due			48,106
Additional Cost Of Company			96,260
Cost			96,260
Managing Director's Agreement [Member]
Payment under the royalty agreement			218
Royalty Payment			122,572
Clinical Study Research Agreement [Member] | In 2018 [Member] | University of Taiwan [Member]
Collaborative Obligations Amount Due			510,000
Collaborative Obligations Amount			$ 2,550,000
Lease Agreement Expire Period			three-year
Cost			$ 510,000
Restricted Stock Units (RSUs) [Member]
Recognized total compensation expense			1,396,638
RSU Vested in 2024			513,394
RSU Vested in 2023			527,940
RSU Vested in 2025			355,304
Unrecognized compensation expense			168,518
Operating Lease Right of Use Obligations [Member]
Payment Of Lease Liabilities			185,692
Operating Lease Expense			167,465
Short Term Lease Costs			$ 45,161